A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid) as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy (The Continuum Trial)

Trial Profile

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid) as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia Following Second-Line Therapy (The Continuum Trial)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jun 2018

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms CONTINUUM
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 05 Jun 2018 Results of pooled data from 3 phase III trials (CLLM1, CONTINUUM, ORIGIN), were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 27 Apr 2018 This trial has been completed in Germany (end date: 2017-09-05)
    • 17 Feb 2018 This trial was discontinued in Germany.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top